As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...

Halo Pharma will become a stand-alone business as a result of the sale of the Noramco API and associated business to Siegfried. · GlobeNewswire Inc. SK Capital Partners have signed a definitive ...

The pharmaceutical manufacturing market is poised for growth by leveraging advanced technologies, digital platforms, and robust supply chain strategies. Opportunities arise in adopting ...

The genesis of a small molecule drug is often an international affair. The medication might begin its life at an active pharmaceutical ingredient (API) manufacturing facility in Puerto Rico, then stop ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today reported strong growth in 2022 in both its ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions ...